key: cord-0732827-4d8gtg10
authors: Dhillon, P. S.; Dineen, R.; Morris, H.; Tanasescu, R.; Nikfekr, E.; Evans, J.; Constantinescu, C. S.; Hosseini, A. A.
title: Neurological Disorders associated with COVID-19 Hospital Admissions : Experience of a Single Tertiary Healthcare Centre
date: 2020-12-11
journal: nan
DOI: 10.1101/2020.11.22.20235184
sha: bfeb8126cfdca178710aa2a505d69d808038a29b
doc_id: 732827
cord_uid: 4d8gtg10

Background: Early reports have detailed a range of neurological symptoms in patients with the SARS-CoV-2 infection. However, there is a lack of detailed description and incidence of the neurological disorders amongst hospitalized COVID-19 patients. We describe a range of neurological disorders (other than non-specific neurological symptoms), including their clinical, radiological and laboratory findings, encountered in our cohort COVID-19 patients admitted to a large tertiary institution. Methods: We reviewed our prospectively collated database of all adult Neurology referrals, Neurology and Stroke admissions and Neurological multi- disciplinary team meetings for all hospitalized patients with suspected or proven COVID-19 from 17 March 2020 to 31 August 2020. Results: Twenty-nine of 1243 COVID-19 inpatients (2.3%) presented with COVID-19-related neurological disorders. The mean age was 70.6 +/- 13.5(SD) years, age range of 46-97 years, and there were 17 males. 22 patients had confirmed, 5 were probable and 2 had suspected COVID-19 infection according to the WHO case classification. Eight patients (27%) required critical care admission. Neurological symptoms at presentation included acute confusion and delirium, seizures, and new focal neurological deficits. Based on the pre-defined neurological phenotype, COVID-19 patients were grouped into four main categories. 16 patients had cerebrovascular events (13 with acute ischaemic stroke and 3 had haemorrhagic features), 7 patients were found to have inflammatory, non-inflammatory and autoimmune encephalopathy (including 2 with known Multiple Sclerosis), whilst movement and peripheral nervous system disorders were diagnosed in 3 patients each. Conclusion: Although the exact prevalence and aetiology remains unclear, non- sporadic new onset of neurological disorders, in addition to anosmia, occurs during the acute COVID-19-infection. Longitudinal follow-up of these patients is required to determine the long-term effects, treatment response and outcome of the SARS-CoV-2 infection.

Thirteen of the 28 patients (46%) with an age range of 34-97 years, and 7 females, were diagnosed with acute ischaemic stroke, 5 of which were large vessel occlusions involving the middle cerebral artery (MCA). Only one patient presented with a posterior circulation stroke whilst two had multifocal infarcts.

All but one patient had at least one known cardiovascular risk factor. Two patients were admitted in the intensive care unit for management of a malignant MCA syndrome. All patients underwent a computed tomography (CT) and/or an MRI Head at presentation (representative examples in Figure 1 ). Only two patients were given intravenous (IV) thrombolysis and two underwent All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in showed cerebral microbleeds (CMB) in the splenium of the corpus callosum and subcortical white matter ( Figure 2 ). Both patients were placed on continuous veno-venous haemofiltration (CVVH) but neither required extracorporeal membrane oxygenation (ECMO). The platelet count level, prothrombin and activated partial thromboplastin times were within the normal referenced ranges.

The third patient in her 50s (Patient 24) presented with recurrent seizures. The MRI Head also revealed CMB, without any other diagnostic features of cerebral amyloid angiopathy. No critical care admission was required and the prothrombin time was normal. Two patients (Patient 24 and 28) made an uneventful recovery. However, Patient 18 reported unilateral hearing impairment following hospital discharge.

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 11, 2020. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 11, 2020. ;  

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 11, 2020. ;

We report a variety of neurological disorders with a clinical impact in patients with COVID-19 infection admitted in a large tertiary institution during the 'first wave' of the COVID-19 pandemic in the UK. There have been isolated reports of various neurological disorders associated with previous outbreaks of the severe acute respiratory syndrome (SARS) and Middle East acute respiratory syndrome (MERS) (19, 20) . Similarly, our cohort of cases demonstrates a wide range of Evidence from our cohort and recent studies have included non-specific initial presentations such as altered mental status or delirium, features commonly seen in the critically unwell with sepsis and hypoxaemia, as well as being potential early signs of dementia. The neurological disorders have been reported in patients who present solely with neurological signs and symptoms as well as All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 11, 2020. those with established systemic or pulmonary illness related to COVID-19. These neurological features may precede or occur days after the onset of pulmonary symptoms. Hence, the variable and non-specific nature of the presentation and onset of the illness creates a diagnostic and therapeutic dilemma. Furthermore, the occasional delay of presentation and hospital admission during the first peak of the pandemic due to patients' fear, isolation or shielding, may have lead to an increase in severity of the infection and neurological disorders at the point of diagnosis. Interestingly, there was no increased incidence or severity of the COVID-19 infection or neurological disorders amongst the BAME group in our cohort. However, this could be due to the relatively small number of BAME communities in our geographical region.

There has been a reported increase in the incidence and severity of cerebrovascular disease associated with COVID-19, particularly in a younger cohort (6, 21) . Our cohort demonstrated a high percentage of patients with acute ischaemic stroke and up to 38% of these had a large vessel occlusion. Some of the acute ischaemic cerebrovascular events with multifocal infarcts may be cardioembolic in nature, due to associated cardiovascular risk factors, but coagulopathy, vasculitis and viral endothelialitis have also been reported as potential causes of multi-vessel stroke in patients with 22) . The hyper-inflammatory syndrome or 'cytokine storm' strongly associated with severe COVID-19 infection could also contribute to the underlying aetiology (13) .

Thrombotic microangiopathy and endothelial dysfunction, also evident in multiple organ systems related to COVID-19, may be contributory factors in All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 11, 2020. ; https://doi.org/10.1101/2020.11.22.20235184 doi: medRxiv preprint sepsis/critical illness-related CMBs (22, 23) . The SARS-CoV-2 has been shown to preferentially bind to the angiotensin converting enzyme (ACE)-2 receptors that can be found in the endothelial lining, leading to the breakdown of the bloodbrain barrier (8) . However, cerebral CMBs have similarly been reported in acute respiratory distress syndrome patients with a resemblance seen in CMB-related high altitude exposure, sharing a common underlying aetiology of hypoxaemia (24) . This could likewise explain the findings in our cases with haemorrhagic neurological manifestations in COVID-19. Interestingly, both patients with isolated intraventricular haemorrhage had normal coagulation parameters, and the observed CMBs were atypical for hypertensive or amyloid angiopathy causes.

Other variables that may influence the presence and/or extent of microhaemorrhage in patients with COVID-19 include therapeutic anticoagulation and raised cerebral venous pressure secondary to ventilator measures in optimising patient oxygenation in the critical care setting (18) .

The neurotropic potential of COVID-19 via direct viral axonal injury has been alluded to following scarce reports of the SARS-CoV-2 being detected in the CSF of patients with meningo-encephalitis and in animal models (25, 26) . Similarly, few case reports have demonstrated imaging features of direct neuronal injury of the olfactory pathway in COVID-19 patients presenting with anosmia, adding strength to this potential mechanism (27) . Nonetheless, no detectable intrathecal coronavirus strain was identified in our patients who presented with encephalopathy.

Interestingly, two patients who required critical care admission reported new onset hearing loss following hospital discharge, despite no acute abnormality All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 11, 2020. ; https://doi.org/10.1101/2020.11.22.20235184 doi: medRxiv preprint reported on the admission MRI Head. A recent case report also described a possible association between sensorineural hearing impairment and COVID-19 in the critical care setting (28) . It is postulated that such an observation could be due to the underlying hyperinflammatory process and/or the neuro-invasive potential of the SARS-CoV-2 against the auditory nervous system. Hence, it will be important to consider screening patients with severe COVID-19 infection for hearing impairment during the hospital admission.

An immunological response secondary to the SARS-CoV-2, resulting in cerebral inflammation and oedema with clinical encephalopathic features may offer an alternative explanation for the incidence of inflammatory and auto-immune encephalopathy disorders (14, 29) . Antibodies against neuronal synaptic proteins have been demonstrated in autoimmune encephalitis, and there have been increased numbers of antibodies reported against other coronavirus strains, suggesting a possible association between auto-immune or inflammatory encephalopathic disorders and the COVID-19 infection (30, 31) . Furthermore, the presence of both intrathecal and serum oligoclonal bands in two patients with acute encephalitis and ADEM suggests that the immune-mediated response is not restricted to the intrathecal production of immunoglobulins. Postinfectious autoimmune disorder is also demonstrated in our case cohort of GBS, whereby the onset of neurological symptoms followed an initial period of illness related to COVID-19. Expected electrophysiological changes in keeping with demyelinating peripheral neuropathy was confirmed and the anticipated response to the IV immunoglobulin therapy was observed.

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 11, 2020. ;  Limitations of our study include its lack of pathological evidence to prove causality. Furthermore, we only included hospitalised patients with COVID-19 in our study, thereby potentially underestimating the true incidence of the neurological associations in patients in the community. There were also inherent drawbacks in the sensitivity and specificity of the available RT-PCR swab tests during the study period, which may have underestimated the incidence of COVID-19 in the patient population (32) . All rights reserved. No reuse allowed without permission.

perpetuity.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

The copyright holder for this this version posted December 11, 2020. ; https://doi.org/10.1101/2020.11.22.20235184 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 11, 2020. ; https://doi.org/10.1101/2020.11.22.20235184 doi: medRxiv preprint perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 11, 2020. ; https://doi.org/10.1101/2020.11.22.20235184 doi: medRxiv preprint Overall features are in keeping with acute demyelinating encephalomyelitis. All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 11, 2020. ; https://doi.org/10.1101/2020.11.22.20235184 doi: medRxiv preprint

WHO Director-General's opening remarks at the media briefing on COVID-19 -11

COVID-19) in the UK

Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease

Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study

Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young

Cerebrovascular Disease in COVID-19

The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings

Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study

Disseminated intravascular coagulation in patients with 2019-nCoV pneumonia

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Risk of myocardial infarction and stroke after acute infection or vaccination

COVID-19: consider cytokine storm syndromes and immunosuppression

COVID-19 : Notice under Regulation 3(4) of the Health Service (Control of Patient Information) Regulations

World Health Organization (WHO) COVID-19 Case definition 7

Delirium as a presenting feature in COVID-19: Neuroinvasive infection or autoimmune encephalopathy?

Hemorrhagic Neurologic Manifestations in COVID-19: An Isolated or Multifactorial Cause?

Neurological manifestations in severe acute respiratory syndrome

Cerebrovascular disease in patients with COVID-19: neuroimaging, histological and clinical description

Neuroimaging Findings in Patients with COVID-19

Brain MRI Findings in Severe COVID-19: A Retrospective Observational Study

A first case of meningitis/encephalitis associated with SARS-Coronavirus-2

The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients

Olfactory Bulb Signal Abnormality in Patients with COVID-19 Who Present with Neurologic Symptoms

Sudden irreversible hearing loss post COVID-19

Nervous system involvement after infection with COVID-19 and other coronaviruses

Autoimmune encephalopathies

Coronavirus immunoreactivity in individuals with a recent onset of psychotic symptoms

Effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2, to inform COVID-19 diagnosis: a rapid systematic review

 Table 4 Three patients with Peripheral nervous system disorders. GBS = Guillain-Barre syndrome NR = no result. CRP = C-Reactive protein. mRS = modified Rankin Score NMDA = N-methyl-D-aspartate, PCR = polymerase chain reaction, LGI-1 = Leucine-rich glioma inactivated-1, CASPR = contactin-associated protein-like 2 M = male F = female